Aprea Therapeutics Initiates Twice Daily Dosing of ATRN-119 in Phase 1/2a Clinical Trial to Enhance Cancer Treatment Efficacy
Aprea Therapeutics initiates twice daily dosing of ATRN-119 in cancer trial to enhance efficacy and optimize patient outcomes.Quiver AI SummaryAprea Therapeutics has initiated a twice daily dosing regimen...
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board
/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...
Biotech Bid Up Following First Patient Dosage
A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...